Health Care & Life Sciences » Pharmaceuticals | Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB | Income Statement

Fiscal year is January-December. All values SEK Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
2,177
2,607
3,228
5,204
6,511
9,139
Cost of Goods Sold (COGS) incl. D&A
1,178
1,354
1,523
1,981
2,314
2,887
Gross Income
998
1,253
1,705
3,224
4,197
6,252
SG&A Expense
1,066
1,237
1,556
2,127
2,533
3,129
EBIT
71
41
-
-
1,665
3,122
Unusual Expense
-
294
-
-
12
-
Non Operating Income/Expense
3
68
9
43
56
16
Interest Expense
60
57
59
93
66
60
Pretax Income
123
319
84
1,048
1,532
3,082
Income Tax
30
51
19
246
384
664
Consolidated Net Income
93
268
65
802
1,149
2,418
Net Income
93
268
65
802
1,149
2,418
Net Income After Extraordinaries
93
268
65
802
1,149
2,418
Net Income Available to Common
93
268
65
802
1,149
2,418
EPS (Basic)
0.35
1.01
0.24
2.99
4.27
8.97
Basic Shares Outstanding
265
266
267
268
269
270
EPS (Diluted)
0.35
1.01
0.24
2.98
4.25
8.93
Diluted Shares Outstanding
265
266
267
269
270
271
EBITDA
234
272
468
1,537
2,139
3,607
Other Operating Expense
4
57
-
-
-
-
Non-Operating Interest Income
4
4
3
1
1
3

About Swedish Orphan Biovitrum AB

View Profile
Address
Tomtebodavägen 23A
Solna AB 112 76
Sweden
Employees -
Website http://www.sobi.com
Updated 07/08/2019
Swedish Orphan Biovitrum AB engages as a biopharmaceutical company. It provides therapies and services for patients with rare diseases. The firm's core products include Kineret within the inflammation therapeutic area; and Orfadin, Ammonaps, and Ammonul within the genetics and metabolic therapeutic area.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.